High Prevalence of Human Parvovirus 4 Infection in HBV and HCV Infected Individuals in Shanghai by Yu, Xuelian et al.
High Prevalence of Human Parvovirus 4 Infection in HBV
and HCV Infected Individuals in Shanghai
Xuelian Yu
1, Jing Zhang
3, Liang Hong
3, Jiayu Wang
1, Zhengan Yuan
2, Xi Zhang
1., Reena Ghildyal
4*
.
1Microbiology Laboratory, Hongkou District Center for Disease Control and Prevention, Shanghai, People’s Republic of China, 2Shanghai Municipal Center for Disease
Control and Prevention, Hongkou District Center for Disease Control and Prevention, Shanghai, People’s Republic of China, 3Microbiology Laboratory, Hongkou District
Center for Disease Control and Prevention, Shanghai, People’s Republic of China, 4Respiratory Virology Group, Centre for Research in Therapeutic Solutions, Faculty of
Applied Science, University of Canberra, Canberra, Australia
Abstract
Human parvovirus 4 (PARV4) has been detected in blood and diverse tissues samples from HIV/AIDS patients who are
injecting drug users. Although B19 virus, the best characterized human parvovirus, has been shown to co-infect patients
with hepatitis B or hepatitis C virus (HBV, HCV) infection, the association of PARV4 with HBV or HCV infections is still
unknown. The aim of this study was to characterise the association of viruses belonging to PARV4 genotype 1 and 2 with
chronic HBV and HCV infection in Shanghai. Serum samples of healthy controls, HCV infected subjects and HBV infected
subjects were retrieved from Shanghai Center for Disease Control and Prevention (SCDC) Sample Bank. Parvovirus-specific
nested-PCR was performed and results confirmed by sequencing. Sequences were compared with reference sequences
obtained from Genbank to derive phylogeny trees. The frequency of parvovirus molecular detection was 16–22%, 33%
and 41% in healthy controls, HCV infected and HBV infected subjects respectively, with PARV4 being the only parvovirus
detected. HCV infected and HBV infected subjects had a significantly higher PARV4 prevalence than the healthy population.
No statistical difference was found in PARV4 prevalence between HBV or HCV infected subjects. PARV4 sequence
divergence within study groups was similar in healthy subjects, HBV or HCV infected subjects. Our data clearly
demonstrate that PARV4 infection is strongly associated with HCV and HBV infection in Shanghai but may not cause
increased disease severity.
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Introduction
Parvovirus 4 (PARV4) is a DNA virus belonging to the
Parvoviridae family, and was first identified in 2005 [1]. PARV4
consists of two genotypes sharing 95% nucleotide identity, with the
original PARV4 being classified into genotype 1 and the newly
discovered PARV5 into genotype 2. Parvoviridae also includes B19,
the first described human parvovirus, which causes erythema
infectiosum and the recently described human Bocavirus (HboV)
which is associated with lower respiratory tract infections.
PARV4 DNA has been detected in samples of pooled plasma
from various manufacturers [2,3,4,5] in different countries. So far,
PARV4 DNA has been restricted to subjects with a parenteral
exposure history suggesting a predominantly or exclusively
parenteral route of transmission [4,6,7]. In one study, PARV4
DNA has been detected in blood samples from cadavers of
injecting drug users who were also HCV RNA positive [8]. Taken
together with previous work showing that B19 is able to co-infect
with HCV, this suggests that PARV4 might be able to co-infect
with HCV with possible implications for disease severity.
In this study we have investigated the prevalence of PARV4 in
healthy adults, HCV and HBV infected subjects, examined the
predominant genotype of the virus causing PARV4 infection in
Shanghai and its association with HCV and HBV infection.
Methods
Study Groups
In our study, we used 153 serum samples from HCV positive,
248 from HBV positive patients and 289 from healthy individuals
matched for age and year of sample collection. Sera positive for
HCV IgM antibody (Anti-HCV IgM) and negative for HBV S
antigen (HBsAg) were termed HCV infected subjects (Numbered
from HCV001-HCV153); sera negative for both Anti-HCV IgM
and HBsAg collected in year of 2008 were chosen as controls for
HCV-infected subjects (Numbered from H08001-H08096); sera
positive for HBsAg, but negative for HBe antigen (HBeAg) and
anti-HCV IgM were termed HBV infected subjects (Numbered
from HBV001-HBV188); sera negative for both anti-HCV IgM
and HBsAg collected in year of 2009 were chosen as controls for
HBV infected subjects (Numbered from H09001-H09193). Sixty
sera positive for both HBsAg and HBeAg detection were classed as
Chronic HBV Infection. All samples were retrieved from
Shanghai Centers for Disease Control and Prevention (SCDC)
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study and all laboratory testing with samples was approved by
SCDC Ethical Review Committee. All work involving human
samples was approved by the Ethical Review Committee,
Shanghai Municipal Center for Disease Control and Prevention.
The samples were collected as part of routine surveillance activities
undertaken by SCDC, and consent waived by the Ethical Review
Committee.
Serological ELISA Assays
Anti-HCV IgM and HBsAg were assayed in all serum samples
used. HBeAg was assayed in sera positive for HBsAg. Anti-HCV
IgM, HBsAg and HBeAg were assayed using commercial ELISA
kits (Diagnostic Kit for Anti-HCV IgM, HBsAg and HBeAg from
Kehua Cooperation, Shanghai). Experiments were performed as
per manufacturer’s recommendations. Positive and negative
controls were included in each test. Any sample with OD of
sample/average OD of negative control $2.1, was taken as
positive.
PARV4 PCR
The total DNA of each sera sample (200 ml) was isolated on the
MagNA Pure LC 2.0 (Roche, Switzerland) using MagNA Pure LC
DNA Isolation Kit (Roche, Germany) following manufacturer’s
recommendations; 60 ml of eluted DNA was used as template for
PCR.
PARV4 nested PCR was performed in all samples using
previously described primers PV4ORF1F and PV4ORF1R (outer
primers) [3] and PV4NS1Fn2 and PV4NS1Rn2 (inner primers)
[5], with GoTaq PCR Core System II (Promega, USA). PCR
reaction conditions were as previously published [5].
B19 and Bocavirus Real-time PCR
Human Parvovirus (B19) Real Time PCR kit and HBoV Real
Time PCR kit (Both from Shanghai ZJ Bio-Tech Co., Ltd.,
People’s Republic of China) were used to perform B19 and HBoV
real-time PCR respectively, in all sera.
HBV DNA Test and ALT Assay
Serum specimens of chronic HBV patients were tested for
presence of viral DNA with a Real Time PCR Quantitation kit (ZJ
Bio-Tech, Shanghai). The PCR mix was amplified by Roche Light
Cycler 480 (Roche, Switzerland). Alanine aminotransferase (ALT)
was assayed in sera from chronic HBV patients using commercial
kits (Kehua Cooperation, Shanghai) detected by the Synchron
CXH 5 PRO Clinical Systems (Beckman, USA). Experiments were
performed as per instructions; positive and negative controls
provided by the company were included in each test. Serological
positivity was accepted at titers $64 units per liter (U/L).
Sequencing and Phylogenetic Analysis
Identity of nested PCR products was confirmed by sequencing.
PCR amplicons from 1564 to 1724 bp of ORF1 were sequenced
by Biosune Company using the internal primers (BioSune,
Shanghai). Sequences were analyzed by CLC Sequence Viewer
6 [9]. To facilitate phylogenetic analysis, PARV4 (PARV4
genotype 1; AY622943.1 and EU546211.1) and PARV5 (PARV4
genotype 2) sequences (DQ112361.1 and DQ873391.1) were
downloaded from GenBank.
Data Analysis
Data were processed by SPSS for Windows version 13.0.
Differences between nominal or ordinal variables were tested by
the Pearson’s Chi-Square test. Continuous numeric data were
compared by t test or nonparametric Kruskal-Wallis Chi-Square
test. Significance was accepted at p#0.05.
Results
Study subjects
The general information regarding study subjects is listed in
Table 1. Groups were compared for gender and age distribution.
65.4% (100/153) of the HCV infected subjects and 67.6% (65/96)
of matched controls were male (p=0.703). Similarly, there was no
difference in the gender distribution between HBV infected
subjects and matched controls (p=0.590). HCV infected subjects
had the median age of 44.5 years, which was not different from
that of matched controls (41 years; p=0.227). The median age of
HBV infected subjects was 41 years and did not differ from that of
controls (36 years; p=0.221).
B19 and Bocavirus Real-time PCR
Neither B19 nor HBoV were detected in serum samples from
HBV, HCV infected subjects or their corresponding healthy
controls.
HBV or HCV infected subjects had increased incidence of
PARV4 DNA in sera compared to matched controls
Sera from 33.3% (51/153) of HCV infected subjects but only
16.7% (16/96) of matched controls were positive for PARV4 DNA
(p=0.004, Table 2). There was no difference in the gender
distribution (p=0.336) between HCV infected subjects who were
positive for PARV4 (70.6%; 36/51 male) compared to those who
were negative (62.7%; 64/102 male). Similarly, compared with the
matched control group, PARV4 DNA detection was significantly
higher in HBV infected subjects (p,0.0001), with no difference in
the gender distribution (p=0.122) between HBV infected subjects
positive (60.3%; 47/78 male) or negative (50%; 55/110 male) for
PARV4 (Table 2). Further analysis of PARV4 prevalence among
different groups suggested that frequency of positive PARV4 DNA
Table 1. General information of study subjects.
Characteristic Healthy Controls Patients p Value
Gender
HCV group
Male 67.6% (65/96) 65.4% (100/153) 0.703
Female 32.3% (31/96) 34.6% (53/153)
HBV group
Male 57.0% (110/193) 54.3% (102/188) 0.590
Female 43.0% (83/193) 45.7% (86/188)
Age (years)
HCV group
Median 41 44.5 0.227
IQR 35–47 37–49
Range 16–68 21–57
HBV group
Median 36 41 0.221
IQR 26–46 28–47.5
Range 18–62 17–60
doi:10.1371/journal.pone.0029474.t001
PARV4 Co-Infection with Hepatitis B/C Virus
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e29474test was not different between HCV infected subjects and HBV
infected subjects (p=0.079), or between HCV matched controls
from 2008 and HBV matched controls from 2009 (p=0.283).
PARV4 Infection is not associated with severity of HBV
disease
Statistical analysis showed no difference in frequency of PARV4
DNA detection between the HBV infected (HBV carriers) and
chronic HBV patients (p=0.665), see Table 3. Further statistical
analyses within the 60 chronic HBV patients showed similar
frequency of PARV4 DNA detection between HBV DNA positive
and negative patients (p=0.597) or ALT positive (ALT$64 U/L)
and negative (ALT,64 U/L) patients (p=0.500). PARV4 positive
subjects had an average ALT expression of 94.04 U/L, which was
not significantly different from that of PARV4 negative subjects
(107.3 U/L, p=0.687; see Table 4).
High Sequence Similarity in PARV infecting Healthy, HBV
or HCV infected subjects
Ten sequences were selected from each study group and used to
construct an evolutionary tree (Fig. 1). All 30 study subjects
(Genbank accession number range from HQ267348 to
HQ267375) were infected with PARV4, with nucleotide sequence
homology ranging from 93.8% to 100%. The sequence homology
between study samples and PARV4 genotype 1 reference strains
ranged from 95.7 to 99.5%; between study samples and PARV4
genotype 2 reference strains from 90.1–93.6%. PARV4 detected
in sample H122 showed the highest variability among the study
samples (93.8–95.7%), with 95.7% homology with PARV4
genotype 1 reference sequences, and 90.1% with PARV4
genotype 2 reference sequences. The genetic distances between
PARV4 and HBV59, HCV145 and H009 sequences were slightly
larger than that of other study subjects. When an evolutionary tree
was constructed on the basis of year of collection of samples no
change in strains was observed in successive years.
Discussion
Previous studies have suggested a significant correlation
between HBV and B19 co-infection [10,11]. PARV4 was
originally detected in a HBV infected patient raising the possibility
of an association with HBV infection as has been described for
B19 [1,12]. To determine the association of PARV4 infection with
HBV and HCV infection, we investigated the molecular
prevalence of PARV4 in healthy individuals, HBV-infected
subjects and HCV-infected subjects in Shanghai.
The frequency of PARV4 DNA detection was significantly
higher among HBV infected and HCV infected subjects than
matched controls. Our data demonstrate that PARV4 is probably
able to co-infect with HBV and HCV. However, co-infection with
PARV4 and HBV may not increase the severity of liver
dysfunction in chronic HBV patients as no correlation between
PARV4 prevalence and HBV DNA expression, or between
PARV4 and blood ALT was observed. Our results show a similar
trend to a study from Scotland which did not find any correlation
between immunosuppression and PARV4 viral load or between
PARV4 viral load and CD4 lymphocyte counts or HIV viral loads
Table 2. Detection Rate of PARV4 DNA.
Characteristic PARV4 Positive PARV Negative p Value
Rate Between Patients and Healthy Controls
HCV group
Controls 16.7% (16/96) 83.3% (80/96) 0.004
Patients 33.3% (51/153) 66.7% (102/153)
HBV group
Controls 22.2% (43/193) 77.7% (150/193) ,0.0001
Patients 41.5% (78/188) 58.5% (110/188)
Rate Between Genders
HCV group
Male 70.6% (36/51) 62.7% (64/102) 0.336
Female 29.4% (15/51) 37.3% (38/102)
HBV group
Male 60.3% (47/78) 50.0% (55/110) 0.122
Female 39.7% (31/78) 50.0% (55/110)
Rate Between HBV and HCV, as well as between Healthy Controls
Hepatitis Patients
HCV 33.3% (51/153) 66.7% (102/153) 0.079
HBV 41.5% (78/188) 58.5% (110/188)
Healthy Controls
2008 16.7% (16/96) 83.3% (80/96) 0.283
2009 22.2% (43/193) 77.7% (150/193)
doi:10.1371/journal.pone.0029474.t002
Table 3. General information & PARV4 DNA positive rate of
HBV infected groups.
Characteristic
HBV Infection
(HBsAg
+ HBeAg
2)
Chronic HBV Infection
(HBsAg
+ HBeAg
+) p Value*
Gender
Male 57.0%(107/188) 56.7%(34/60) 0.744
Female 43.0%(81/188) 43.3%(26/60)
Age
Median 41 42 0.245
IQR 28–47.5 36–48
PARV4 DNA
Positive 41.5%(78/188) 38.3%(23/60) 0.665
Negative 58.5%(110/188) 61.7%(37/60)
*p value: data for 2 HBV patient groups was compared with Pearson’s x2- test.
doi:10.1371/journal.pone.0029474.t003
Table 4. The PARV4 nucleic acid frequency in chronic HBV
patients with/without HBV DNA, and with different ALT levels.
Characteristic PARV Positive PARV Negative P Value
HBV DNA
Positive 60.9% (14/23) 39.1% (9/23) 0.597
Negative 67.6% (25/37) 32.4% (12/37)
ALT Quantitative
Mean of ALT (U/L) 94.04 107.30 0.687
ALT Qualitative
Positive (ALT$64 U/L) 52.2% (12/23) 43.2% (16/37) 0.500
Negative (ALT,64 U/L) 47.8% (11/23) 56.8% (21/37)
doi:10.1371/journal.pone.0029474.t004
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Shanghai had contracted PARV4 without any known acute viral
infection symptoms, suggesting that PARV4 infection may often
cause only subclinical infection.
The frequency of detection of PARV4 in sera from healthy
subjects (16.7–22.2%) in our study is significantly higher than that
reported in plasma from healthy blood donors from North
America (5%, 7 of 137) [3] or Europe (none) [13]. Moreover, the
PARV4 DNA prevalence in HCV and HBV infected individuals
in Shanghai is markedly higher than that in highly exposed and
symptomatic HIV patients from USA (33.3–41.5% vs. 6%) [12] or
HCV-infected injecting drug users (IDUs) from London (30%; 3 of
10) [8] similar to that in plasma-derived coagulation factor
concentrates from Germany (33%; 7/21) [14] and lower than that
in the bone marrow and lymphoid organs of HIV-positive
individuals (70%; 17 of 24) from Scotland [13]. Our data are in
agreement with recent data from France where PARV4 DNA was
detectable in 27.3% (6/22) and 38.7% (29/75) of plasma samples
from haemodialysis patients positive for HCV and HBV,
respectively [15]. The high prevalence of PARV4 DNA in
HBV, HCV and HIV-infected subjects may simply reflect a
generally higher exposure to infectious agents in these population
groups. The variation in detection frequency in different countries
may be multifactorial, such as the study sample size, sample types,
the way and time of sample collection and storage, as well as
detection protocols. In our study, the frequency of PARV4
Figure 1. Phylogenetic tree of PARV4 isolates infecting HBV, HCV patients and healthy controls. The nucleotide sequence from 1564 to
1724 bp of ORF1 gene of PARV4 were amplified, sequenced and analyzed. Bootstrap percentages are given at the node of each branch (1000
replicates). Sequences H009, H108, H110, H113, H121, H122, H132, H142, H145 and H147 were from healthy controls. Sequences HBV02, HBV06,
HBV09, HBV25, HBV42, HBV45, HBV50, HBV59, HBV63 and HBV73 were from HBV infected subjects with PARV4 infection. Sequences HCV037,
HCV048,HCV052, HCV065, HCV074, HCV080, HCV112, HCV115, HCV130 and HCV145 were from HCV infected subjects with PARV4 infection.
AY622943.1 and EU546211.1 represent 2 PARV4 genotype 1 reference strains, and DQ112361.11 and DQ873391.1 are sequences of 2 PARV4,
genotype 2 reference strains. All reference strain sequences were downloaded from GenBank.
doi:10.1371/journal.pone.0029474.g001
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samples from 2008 (p=0.283); probably reflecting the loss of
quality due to longer storage period.
HIV-infected IDUs have a high prevalence of PARV4 infection,
both by molecular detection of PARV4 infection and presence of
PARV4 IgG antibody [6,7,16], which suggests that PARV4 may
be transmitted through parenteral routes. We cannot form any
conclusions about the possible transmission mode of PARV4 in
our study with the limited information available. However, given
the high prevalence of PARV4 DNA in sera of healthy subjects in
Shanghai, blood or blood products were probably not the major
route of transmission in our study group; the possibility that
PARV4 may be transmitted via the parenteral route in some
settings, similar to B19, cannot be dismissed [16].
In our study, the median age of study subjects with PARV4
infection was 33.5 (IQR, 25–47), ranging from 23 to 57 which is
different from the reported age range of PARV4 infected
individuals in Edinburgh where all positive samples were from
subject born in the 1960s [13]. Our findings also suggest that
PARV4 may cause persistent infection as the age of the oldest
individual with PARV4 infection was nearly sixty. A recent study
of T cell responses to PARV4 in HCV and HIV positive
individuals suggests that PARV4 infections are common in these
clinical groups and that viral antigen persists to trigger and
maintain T cell responses [17].
Phylogenetic analysis showed that all sequences of PARV4
ORF1 detected in this study clustered together with the two
PARV4 genotype 1 reference strains and had a more distant
phylogenetic relationship with PARV4 genotype 2 (PARV5).
PARV4 genotype 1 may be the only PARV4 causing epidemics in
Shanghai. Interestingly, the PARV4 genotype 1 variants circulat-
ing in Shanghai were substantially more divergent than those in
Edinburgh [13].
Our study found that PARV4 has been circulating in Shanghai
for the past 50 years with up to 22% of the population being
affected. PARV4 had a significantly higher prevalence in HBV
infected and HCV infected compared to healthy subjects. The
pathogenic mechanisms of PARV4 co-infecting with other
persistent pathogens remains to be elucidated.
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